glp 1 without diabetes Semaglutide Shows Secondary Cardiovascular Prevention Benefits in Patients Beyond glycemia: Comparing tirzepatide to

Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells

We dont know the cause yet, and in both trials, it apparently led to a few patients stopping the drug

However, rapid weight loss or nutritional deficiencies caused by these treatments may trigger temporary shedding, such as telogen effluvium

Poor circulation (peripheral vascular disease) that causes leg pain while walking (intermittent claudication)

A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis

The peptide reduces inflammatory cytokines TNF- and IL-6 in gastric tissue, suggesting potential to address reflux-driven inflammation that PPIs don't target